Halozyme is a therapeutically driven biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the endocrinology, oncology, dermatology and drug delivery markets. The company's broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme’s Enhanze™ T... More >>

Date Title   01/19/10 Halozyme Announces Research Alliance with BioAtla for Conditionally Active Biologics 01/06/10 Halozyme to Present at J.P. Morgan Healthcare Conference on January 13 11/06/09 Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme 11/06/09 Halozyme Therapeutics Reports Third Quarter 2009 Financial Results

Date Title Format/Plug-in Support 01/13/10 JPMorgan Healthcare Conference Adobe PDF 11/06/09 Q3 2009 Halozyme Earnings Conference Call Transcript Adobe PDF 10/15/09 Investor R&D Day Presentation Adobe PDF

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Halozyme Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.